Automate Your Wheel Strategy on EQ
With Tiblio's Option Bot, you can configure your own wheel strategy including EQ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EQ
- Rev/Share 0.8544
- Book/Share 0.2972
- PB 1.2347
- Debt/Equity 0.0279
- CurrentRatio 2.7018
- ROIC -1.3545
- MktCap 13108983.0
- FreeCF/Share -0.5189
- PFCF -0.7099
- PE -0.9338
- Debt/Assets 0.0176
- DivYield 0
- ROE -0.7435
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | EQ | Leerink Partners | Outperform | Market Perform | $3 | $1 | March 28, 2025 |
News
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Read More
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
Published: March 27, 2025 by: Benzinga
Sentiment: Negative
Equillium, Inc. EQ released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGVHD).
Read More
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
Published: March 27, 2025 by: Business Wire
Sentiment: Neutral
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The study results did not demonstrate a meaningful difference in complete response (CR) or overal.
Read More
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Equillium (EQ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Equillium (EQ) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Read More
About Equillium, Inc. (EQ)
- IPO Date 2018-10-12
- Website https://equilliumbio.com
- Industry Biotechnology
- CEO Bruce D. Steel
- Employees 35